الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 97 |  |  |
| | | from | 97 | | |
Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide .lk chronic hepatitis to liver cirrhosis, and ultimately to hepatocellular carcinoma (HCC) . Interleukin (IL-23), a member of the IL-12 cytokine family, which is mainly produced by antigen presenting cells as macrophage and dendritic cells, is responsible for inflammatory disorders and plays a critical role against intracellular pathogens, especially viruses. However its role in development of HCV induced liver diseases is not yet fully understood. The aim of work: The aim of this study aim is to assess the level of IL-23 as inflammatory marker in chronic HCV infection and its changes in response to therapy with DAAs. Research Plan:. This cohort study carried out to estimate serum IL23 level among Egyptian patients mono infected with HCV and follow up this level in response to anti-HCV treatment with new DAAs at the end of therapy with respect to SVR. The study group consists of fifty four patients with HCV mono –infection in addition to thirty five age and sex matched control subjects. They were divided into three groups; group (A) includes 22 patients with HCV mono –infection before and after response to DAAs. group (B) includes 32patients with relapsing disease after DAAs. group (C) includes 35 age and sex matched control subjects. Results: Conclusion:. • In conclusion, IL23 can be used as potential markers for evaluating the progression of chronic hepatitis to cirrhosis and HCC following treatment with DAAs.